Your browser doesn't support javascript.
loading
Brief-exposure to preoperative bevacizumab reveals a TGF-ß signature predictive of response in HER2-negative breast cancers.
Varadan, Vinay; Kamalakaran, Sitharthan; Gilmore, Hannah; Banerjee, Nilanjana; Janevski, Angel; Miskimen, Kristy L S; Williams, Nicole; Basavanhalli, Ajay; Madabhushi, Anant; Lezon-Geyda, Kimberly; Bossuyt, Veerle; Lannin, Donald R; Abu-Khalaf, Maysa; Sikov, William; Dimitrova, Nevenka; Harris, Lyndsay N.
Affiliation
  • Varadan V; Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH.
  • Kamalakaran S; Philips Research North America, 345 Scarborough Road, Briarcliff Manor, NY.
  • Gilmore H; Department of Pathology, Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH.
  • Banerjee N; Philips Research North America, 345 Scarborough Road, Briarcliff Manor, NY.
  • Janevski A; Philips Research North America, 345 Scarborough Road, Briarcliff Manor, NY.
  • Miskimen KL; Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH.
  • Williams N; Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH.
  • Basavanhalli A; Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH.
  • Madabhushi A; Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH.
  • Lezon-Geyda K; Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT.
  • Bossuyt V; Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT.
  • Lannin DR; Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT.
  • Abu-Khalaf M; Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT.
  • Sikov W; Warren Alpert Medical School of Brown University, Providence, RI.
  • Dimitrova N; Philips Research North America, 345 Scarborough Road, Briarcliff Manor, NY.
  • Harris LN; Seidman Cancer Center, University Hospitals, Cleveland, OH.
Int J Cancer ; 138(3): 747-57, 2016 Feb 01.
Article in En | MEDLINE | ID: mdl-26284485
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Breast Neoplasms / Transforming Growth Factor beta / Receptor, ErbB-2 / Angiogenesis Inhibitors / Bevacizumab Type of study: Prognostic_studies / Risk_factors_studies Limits: Female / Humans Language: En Journal: Int J Cancer Year: 2016 Type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Breast Neoplasms / Transforming Growth Factor beta / Receptor, ErbB-2 / Angiogenesis Inhibitors / Bevacizumab Type of study: Prognostic_studies / Risk_factors_studies Limits: Female / Humans Language: En Journal: Int J Cancer Year: 2016 Type: Article